J&J-Pharmacyclics' Imbruvica is second breakthrough therapy to win FDA approval

11/13/2013 | Reuters

Johnson & Johnson and Pharmacyclics received the FDA's approval to market Imbruvica, or ibrutinib, for treatment of patients with mantle cell lymphoma who have received at least one other therapy. The approval makes ibrutinib the second drug with breakthrough therapy status to receive the FDA's nod. The drug is also under regulatory review for chronic lymphocytic leukemia.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC